Tenofovir/Emtricitabine (Truvada)
Overview
- A Clinical Overview of Tenofovir/Emtricitabine (Truvada) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health - Prescribing Information for Tenofovir/Emtricitabine (Truvada) (PDF) (May 2007)
From Gilead Sciences, Inc. - Patient Assistance Programs (January 2005)
Having problems paying for Truvada? Visit Gilead's patient assistance program page.
From Gilead Sciences, Inc. - Understanding Two New Once-a-Day Combinations: Truvada and Epzicom (November/December 2004)
Daniel S. Berger, M.D., reviews issues of drug concentrations, adherence and resistance.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network - New Fixed-Dose Once-a-Day Starting Regimens: Interview With Cal Cohen, M.D. (October 26, 2004)
A leading AIDS physician looks at the advantages and disadvantages of Epzicom and Truvada for those who are first starting antiretroviral treatment.
In AIDS Treatment News, from AIDS Treatment News
News
- Gilead Lowers Its No-Profit Drug Prices for Truvada, Viread (August 30, 2005)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Gilead's Fixed-Dose Combination of Truvada + Efavirenz Not Yet Bioequivalent to Drugs Alone (August 10, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - FDA Approves Two Combination Pills, Epzicom and Truvada; Comment on Commercial Race to Once-a-Day Nucleosides (August 23, 2004)
The benefits of once-a-day drugs haven't been adequately weighed against their potential risks, writes AIDS advocate John James.
In AIDS Treatment News, from AIDS Treatment News - FDA Approves Gilead, GlaxoSmithKline Fixed-Dose Combination AIDS Drugs (August 3, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Two New Fixed-Dose Combinations Approved (August 2, 2004)
From U.S. Food and Drug Administration
Research
- Switch Studies (SWEET and BICOMBO) Explore Metabolic Issues (July 25, 2007)
In The 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO - Switching From Zidovudine/Lamivudine to Tenofovir/Emtricitabine: Results of an Uncontrolled Cohort (November 16, 2006)
In 8th International Congress on Drug Therapy in HIV Infection - HIV JournalView: Tenofovir + Emtricitabine + Efavirenz vs. Zidovudine/Lamivudine + Efavirenz (February/March 2006)
An important study by Joel Gallant et al demonstrates the advantage of tenofovir + FTC in first-line therapy.
From The Body PRO - Data Supports Bioequivalence for Once-Daily, Single-Pill, Fixed-Dose Combination of Sustiva and Truvada, Drug Companies Announce (January 9, 2006)
Filing of a new drug application is expected in the second quarter of 2006.
To read PDF, click here
From Bristol-Myers Squibb Company and Gilead Sciences, Inc. - In Head-to-Head International Study, Tenofovir + Emtricitabine Bests Zidovudine/Lamivudine in Tolerability and Convenience (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment - No K65R Mutations in Patients Failing Tenofovir + Emtricitabine (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment - Truvánadu: Does Gilead's Famed 903 Study Really Show You What They Tell You It Shows? (December 2004)
A highly critical examination of the manner in which many clinical trials are designed.
In TAGline, from Treatment Action Group - Little Leap: Gilead 2-in-1 Opens Door to Impending One-Pill Triple Combo (October 2004)
Rob Camp reports on the generally underwhelming news of the launch of Truvada and Epzicom.
In TAGline, from Treatment Action Group
Clinical Management
Clinical Management
  |